KALA PHARMACEUTICALS INC's ticker is KALA and the CUSIP is 483119103. A total of 55 filers reported holding KALA PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $36,000 | -78.4% | 120,841 | 0.0% | 0.00% | -71.4% |
| Q1 2022 | $167,000 | -43.0% | 120,841 | -50.0% | 0.01% | -41.7% |
| Q4 2021 | $293,000 | -52.7% | 241,857 | +2.2% | 0.02% | -56.4% |
| Q3 2021 | $620,000 | -50.5% | 236,757 | +0.2% | 0.06% | -52.2% |
| Q2 2021 | $1,252,000 | -7.1% | 236,257 | +18.2% | 0.12% | -12.9% |
| Q1 2021 | $1,348,000 | +17.3% | 199,954 | +18.0% | 0.13% | +8.2% |
| Q4 2020 | $1,149,000 | +54.2% | 169,429 | +70.6% | 0.12% | +32.6% |
| Q3 2020 | $745,000 | – | 99,288 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Athyrium Capital Management, LP | 1,333,333 | $5,073,000 | 100.00% |
| CAXTON CORP | 1,483,343 | $5,644,000 | 6.36% |
| Polaris Venture Management Co. V, L.L.C. | 1,197,032 | $4,555,000 | 2.59% |
| RA Capital Management | 4,537,478 | $17,265,000 | 1.03% |
| Orbimed Advisors | 3,447,840 | $13,119,000 | 0.25% |
| Matisse Capital | 46,500 | $177,000 | 0.22% |
| PURA VIDA INVESTMENTS, LLC | 332,831 | $1,266,000 | 0.22% |
| Sofinnova Investments, Inc. | 478,206 | $1,819,000 | 0.16% |
| HARBOURVEST PARTNERS LLC | 99,186 | $377,000 | 0.16% |
| ALGERT GLOBAL LLC | 47,195 | $180,000 | 0.07% |